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ABSTRACT 
 
 
Carbapenem and colistin resistance patterns, mechanism and  
molecular epidemiology of Acinetobacter species in Korea 
 
 
Yangsoon Lee 
 
 
 
Department of Medicine 
The Graduate School, Yonsei University  
 
 
 
(Directed by Professor Seok Hoon Jeong) 
 
 
 
Recent increasing carbapenem resistance in Acinetobacter species is very 
worrisome, resulting in a very limited antimicrobial treatment option. Colistin is 
the only potent therapeutic options available for treatment of nosocomial 
infections caused by multi-drug resistant Acinetobacter species. However, 
colistin-resistant Acinetobacter species of clinical isolates were reported. In 
present study, it was investigated that resistance patterns and mechanisms to 
carbapenems and colistin in Acinetobacter species isolated from clinical  
 
 2 
 
specimens from 19 hospitals in six provinces in Korea in 2008, and the 
epidemiological traits of carbapenem-non-susceptible Acinetobacter baumannii 
(CNSAB), as well as the usefulness of phylogenic grouping based on partial 
rpoB gene sequencing in defining the epidemiological traits of CNSAB. 
A total of 547 non-duplicate clinical isolates of Acinetobacter species were 
collected from 19 hospitals. Reduced susceptibility rates to imipenem or 
meropenem were 70% (272/388) for A. baumannii, 5% (4/82) for A. 
nosocomialis, 13% (8/62) for A. pitti, and 0% (0/13) for A. bereziniae. 
Colistin-resistant clinical isolates were one A. baumannii, one A. bereziniae and 
two Acinetobacter genomospecies 14 TU. Molecular characterization of the 272 
CNSAB isolates using multilocus sequencing typing identified five sequence 
types (STs): ST92, ST75, ST137, ST138 and ST69. Those STs were clustered 
into clonal complex 92, sharing alleles at five to six of seven housekeeping gene 
loci. ST92 was the predominant ST and was associated with European clone II 
disseminated worldwide. CNSAB of CC92 carried the blaOXA-23 gene (n = 169), 
the blaOXA-51-like gene preceded by ISAba1 (n = 89) or both (n = 14). Sequence 
-based analysis of the rpoB gene showed single-nucleotide substitutions in zone 
2 of the rpoB gene, resulting in division into five groups (A to E groups). 
Notably, all CNSAB isolates belonged to subgroup B-0 with a G428T 
substitution in zone 2. All of the other isolates belonging to group C, D and E 
were susceptible to carbapenems. 
 3 
 
In conclusion, carbapenem resistance rates of A. baumannii are very high, over 
70%, whereas colistin resistance rate of Acinetobacter species is very low until 
now. CNSAB isolates of CC92 with the G428T substitution in zone 2 of the 
rpoB gene are disseminated nationwide in our country. A. baumannii with the 
G428T substitution in zone 2 may be more likely to acquire carbapenem 
resistance than are other isolates. 
 
 
 
 
 
 
 
 
 
 
 
 
------------------------------------------------------------------------------------------------ 
Key words : Acinetobacter baumannii, clonal complex 92, European clone II, 
multilocus sequence typing, carbapenem, colistin
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I. INTRODUCTION 
 
The genus Acinetobacter consists of strictly aerobic, gram-negative 
coccobacillary rods that are oxidase negative, non-motile, usually nitrate 
negative, and nonfermentative.
1, 2
 The genus Acinetobacter consists of 22 
nomenspecies and at least 11 additional putative species.
3
 Acinetobacter species 
are widely distributed in nature and in the hospital environment. Acinetobacter 
species are generally considered to be nonpathogenic to healthy individuals but 
may cause infections such as pneumonia, bacteremia, and meningitis in 
debilitated individuals.
2, 4
 Acinetobacter baumannii is an opportunistic pathogen  
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and is the most common cause of serious nosocomial infections within the 
genus Acinetobacter, especially those found in intensive care units (ICUs).
3, 5, 6
 
Carbapenems are β-lactam antibiotics that are highly active even against 
Gram-negative bacilli producing extended spectrum β-lactamases or 
hyper-producing AmpC β-lactamases. Therefore, carbapenems are 
recommended as first-line therapy in the treatment of serious infections caused 
by A. baumannii resistant to oxymino-cephalosporins such as ceftriaxone and 
cefotaxime. The recent dissemination of carbapenem-non-susceptible A. 
baumannii (CNSAB) in many parts of the world is therefore very worrisome, 
resulting in limited antimicrobial treatment options.
4, 7, 8
. Carbapenem resistance 
in Acinetobacter species has mainly been ascribed to enzymatic degradation by  
metallo--lactamases (MBLs) including IMPs, VIMs and SIM, or OXA 
carbapenemases including OXA-23, OXA-24, OXA-51, OXA-58 and their 
sequence variants.
9-13
 Nonenzymatic mechanisms including over expression of 
efflux pumps and changes in outer membrane proteins or penicillin-binding 
proteins may also play a role in acquiring carbapenem resistance.
14-16
 The 
chromosome-borne blaOXA-51-like genes are ubiquitous to A. baumannii. The 
blaOXA-51-like genes play a role in carbapenem resistance when an ISAba1 
presents upstream of the gene, while they have little effect on carbapenem 
susceptibility in the absence of this insertion sequence.
17, 18
 Colistin and 
polymixin B are the only potent options available for treatment of nosocomial 
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infections by multi-drug resistant A. baumannii isolates. However, Ko et al.
19
 
reported high rates of resistance to colistin and polymixin B in subgroups of A. 
baumannii isolates. 
Worldwide dissemination of carbapenem-resistant European clones I and II 
(EU-I and EU-II) has been reported.
20
 Mugnier et al.
21
 identified eight EU-I 
isolates of sequence type (ST) 25, ST44, or two novel STs, as well as ten EU-II 
isolates of ST92 (ST22 was moved to ST92 after an update of allelic profiles at 
PubMLST website, http://pubmlst.org) or ST118 (moved from ST53) in 20 A. 
baumannii isolates carrying the blaOXA-23 gene, originating from 15 countries. 
Wide dissemination of CNSAB isolates of ST92 and its single-locus variants 
have also been described in China and Korea.
22, 23
 Nemec et al.
24
 found that 20 
isolates carrying blaOXA-58-like, blaOXA-24-like, or blaOXA-51-like genes preceded 
by ISAba1 from 23 A. baumannii isolates with carbapenem MICs of  8 g/mL 
isolated from Czech Republic belonged to EU-II. Dissemination of EU-II 
isolates carrying the blaOXA-58 gene in ICUs in Rome has also been reported.
25
 In 
contrast, Kulah et al.
26
 reported that multiple clones of A. baumannii carrying 
the blaOXA-58 gene were responsible for a sustained outbreak that occurred in a 
hospital in Turkey; however, those isolates were not associated with the A. 
baumannii EU-I, EU-II, or EU-III strains. 
Scola et al.
27
 demonstrated the usefulness of RNA polymerase -subunit (rpoB) 
gene sequencing in the differentiation and identification of Acinetobacter spp. 
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Ko et al.
19
 reported that A. baumannii isolates could be divided into three 
subgroups (I, II, or III) based on phylogenic grouping inferred from the 
sequence of a variable region, zone 2, in the rpoB gene. Furthermore, they 
reported that the grouping correlated with antimicrobial resistance profiles. 
While most isolates of subgroup I were susceptible to colistin and polymyxin B, 
many isolates of subgroups II and III exhibited resistance to these drugs. 
However, they did not focus on correlations between the grouping and 
carbapenem resistance profiles in A. baumannii. 
The aims of this study were to investigate: (1) carbapenem and colistin 
resistance patterns and mechanisms according to Acinetobacter species isolates 
from clinical specimens of patients hospitalized at 19 different hospitals in 
Korea, (2) the epidemiological traits of CNSAB isolates, and (3) the usefulness 
of phylogenic grouping based on partial rpoB gene sequencing in defining the 
epidemiological traits of CNSAB.  
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II. MATERIALS AND METHODS 
 
1. Bacterial isolates and reference strains 
A total of 547 clinical isolates of Acinetobacter spp. were collected from 19 
different hospitals in six provinces of Korea in 2008. During those periods, the 
isolates were consecutively collected at each hospital and recovered from one 
isolate per patient. The strains were isolated from blood, sputum, wound and 
urine specimens. The isolates were identified by either conventional methods or 
the ATB 32 GN system (bioMérieux, Marcy l’Etoile, France) and 16S-23S 
rRNA intergenic spacer region sequencing.
2, 28
 
 
2. Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed using the CLSI disk 
diffusion methods. The antimicrobial disks used were imipenem (Becton 
Dickinson, Sparks, MD, USA) and meropenem (Becton Dickinson). MICs of 
colistin (Sigma-Aldrich, St.Louis, Mo, USA) were determined using the agar 
dilution method according to CLSI guidelines.
29  
E. coli ATCC 25922, P. 
aeruginosa ATCC 27853, A. baumannii ATCC 19606 and Acinetobacter 
genomospecies 14TU ATCC 17905 were used as the control strains.  
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3. Investigation of carbapenem resistance mechanisms 
A. Screening for carbapenemase production  
The modified Hodge test was performed on MacConkey agar plates as 
described previously for the screening of carbapenemases.
30
 Briefly, the 
indicator organism, E. coli ATCC 25922, at a turbidity of 0.5 McFarland 
standard, was used to swab inoculate the surface of a MacConkey agar plate 
(Becton Dickinson), and the test strain was heavily streaked from the center to 
the plate periphery. After the plate was allowed to stand for 15 min at room 
temperature, a 10-μg imipenem disk (Becton Dickinson) was placed at the 
center, and the plate was incubated overnight. The presence of a distorted 
inhibition zone was interpreted as a positive result for carbapenem hydrolysis 
screening. 
The imipenem and EDTA-sodium mercaptoacetic acid (SMA) double-disk 
synergy (IEDDS) test were performed on Mueller-Hinton agar plates as 
described previously for the screening of and MBLs.
30
 Briefly, a 10-μg 
imipenem disk (Becton Dickinson) was placed on Mueller-Hinton agar plate, 
and a blank filter paper disk added 10 μL of 0.5 M EDTA and SMA solution 
was placed at a distance of 10 mm a blank filter paper disk. After overnight 
incubation, the presence of even a small synergistic inhibition zone was 
interpreted as positive. 
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B. Detection of OXA carbapenemase and MBL genes 
A few isolated colonies of test organism were suspended in 100 μL of distilled 
water and then boiled for 10 min to extract DNA. After centrifugation for 2 min 
at 13,000 rpm, the supernatant was used as a template. PCR premix 
(Accupower
®
 PCR Premix, Bioneer, Daejeon, Korea) was used for PCR 
reaction. Multiplex PCR was performed to detect blaOXA genes as described by 
Woodford et al.
31
 Multiplex PCR was done using PCR primer sets listed in 
Table 1. PCR condition was as follows; 94C for 5 min, 94C for 25 sec, 52C 
for 40 sec, 72C for 50 sec for 30 cycles and final extension at 72C for 6 min. 
PCR product was identified in 1.5% agarose gel electrophoresis stained with 
ethidium bromide. Product sizes expected were 501 bp (OXA-23-like gene), 
246 bp (OXA-24-like gene), 353 bp (OXA-51-like gene) and 599 bp 
(OXA-58-like gene). To detect any upstream presence of ISAba1, primer 
ISAba1-F in combination with reverse primers for the relevant blaOXA-51-like 
gene. 
PCR experiments were carried out to detect the genes encoding MBLs (IMP-1 
variants, VIM-2 variants, and SIM-1) as described previously
32
. PCR condition 
was as follows; 94C for 5 min, 94C for 30 sec, 52C for 40 sec, 72C for 50 
sec for 35 cycles and final extension at 72C for 5 min. The nucleotide 
sequences were analyzed using PCR-generated amplicons at a commercial 
laboratory (Macrogen, Seoul, Korea). 
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Table 1. Primers used for detection and sequencing of OXA carbapenemases 
and metallo-β-lactamases  
Targets Primers Sequence (`5 to 3`) 
OXA-23-like OXA-23-F GATCGGATTGGAGAACCAGA 
 OXA-23-R ATTTCTGACCGCATTTCCAT 
OXA-24-like OXA-24-F GGTTAGTTGGCCCCCTTAAA 
 OXA-24-R AGTTGAGCGAAAAGGGGATT 
OXA-51-like OXA-51-F TAATGCTTTGATCGGCCTTG 
 OXA-51-R TGGATTGCACTTCATCTTGG 
OXA-58-like OXA-58-F AAGTATTGGGGCTTGTGCTG 
 OXA-58-R CCCCTCTGCGCTCTACATAC 
blaVIM VIM-F GATGGTGTTTGGTCGCATA 
 VIM-R CGAATGCGCAGCACCAG 
blaIMP IMP-F GGAATAGAGTGGCTTAAYTCTC 
 IMP-R CCAAACYACTASGTTATCT 
blaSIM SIM-F TACAAGGGATTCGGCATCG 
 SIM-R TAATGGCCTGTTCCCATGTG 
ISAba1 ISAba1-F CACGAATGCAGAAGTTG 
 ISAba1-R CGACGAATACTATGACAC 
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C. blaOXA-23 gene location 
(A) Pulsed-field gel electrophoresis and Southern blotting 
Strains were cultured onto a Muller-Hinton agar media for 18-20 h. Harvested 
cells suspended into 1 mL of saline-EDTA solution (0.15 M NaCl, 10 mM 
EDTA, pH 8.0) were centrifuged at 12,000 rpm for 5 min. Sediment cells  
were added 130 μL of cold Pett IV buffer (1 M NaCl, 10 mM EDTA, pH 8.0) 
and 2 μL of lysozyme (10 mg/mL). After that, 165 μL of 2% InCert agarose 
(Cambrex Bio Science Rockland, Inc. Rockland, ME, USA) was added and 
transferred into the plug mold, and harden at 4C for 10 min. A plug was 
divided into 3 pieces and lysed with 1 mL of lysozyme and 1 mL of proteinase 
K 10 μL plus ES solution (1% N-lauroyl-sarcosine, 0.25M EDTA, pH 8.0) 1 mL 
at 50C overnight. Samples added 1.5 mL of 1 mM phenylmethylsulfonyl 
fluride in TE buffer (10 mL Tris-HCl, 1 mM EDTA, pH 8.0) solution were 
incubated for 4 h and washed three times, each for 10 min, in 1 mL of TE buffer. 
Plug was washed once for 50 min, in 1 mL of 0.1 mM EDTA-TE buffer. Plugs 
containing whole genomic DNA of the isolates were digested with S1 nuclease 
or I-CeuI restriction enzyme. DNA fragments were separated using PFGE with 
a CHEF-DRII device (Bio-Rad, Hercules, CA, USA). PFGE was performed at 6 
V/cm for 20 h with pulse times ranging from 9 to 90 s at a temperature of 14C. 
PFGE was performed in 1% agarose gel electrophoresis and stained with 
ethidium bromide for 30 min. The gels with S1 nuclease-treated linearized 
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plasmids and I-CeuI-digested chromosomal DNA were blotted onto nylon 
membranes (Bio-Rad) and hybridized with probes specific for the blaOXA-23 gene 
or 16S rRNA gene. The probes were obtained via PCR experiments as described 
above. Probe labeling, hybridization, and detection were performed with the 
DIG DNA Labeling and Detection kit (Roche Diagnostics, Indianapolis, IN, 
USA). 
 
4. Evaluation of molecular epidemiologic traits 
A. Repetitive sequence-based PCR 
Repetitive sequence-based PCR (rep-PCR) experiments were performed using 
the DiversiLab system (bioMérieux Inc., Grenoble, France) according to the 
manufacturer’s instructions to investigate the clonal relatedness of A. baumannii 
isolates. Briefly, the whole microbial DNA using beads were extracted, and 
rep-PCR amplification was performed in a thermal cycler. PCR product was 
loaded in the DNA chip and run in the Agilent
®
 2100 Bioanalyzer. Results were 
analyzed with DiversiLab software using the Kullback-Leibler method to 
determine distance matrices and the unweighted pair group method with 
arithmetic averages to create a dendrogram. Isolates showing >95% similarity 
were considered to be related.
33
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B. Multilocus sequence typing 
Multilocus sequence typing (MLST) was performed using the method of 
Bartual et al.
34
 Fragments of seven housekeeping genes (gltA, gyrB, gdhB, recA, 
cpn60, gpi, and rpoD) were amplified by PCR and sequenced. Two primer sets 
were redesigned to detect gpi and rpoD genes (Table 2). Multiplex PCR 
condition was as follows; 94C for 5 min, 94C for 1 min, 55C for 1 min, 72C 
for 2 min for 30 cycles and final extension at 72C for 2 min. PCR products 
loaded in 1.5% agarose gel were extracted using QIAquick gel extraction kit 
(Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions. 
The nucleotide sequences were analyzed using PCR-generated amplicons at a 
commercial laboratory (Macrogen). Allele numbers were assigned a sequence 
type after the distinct allele sequences were submitted to a dedicated database 
(http://pubmlst.org). A clonal complex (CC) was used to assess the genetic 
relatedness of the STs; the most stringent definition - sharing alleles at six of 
seven loci - was used.
35
 MLST described by Diancourt et al.
36
 was performed 
for representative strains allocated to the STs associated with CNSAB. Allelic 
profiles of seven housekeeping genes (cpn60, fusA, gltA, pyrG, recA, rplB and 
rpoB) were analyzed using Acinetobacter MLST database (http://www.pasteur. 
fr/recherche/genopole/PF8/mlst/). 
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Table 2. Primers used for detection and sequencing of seven housekeeping 
genes using MLST analysis 
Targets Primers Sequence (`5 to 3`) 
gltA  gltA-F AATTTACAGTGGCACATTAGGTCCC 
 gltA-R GCAGAGATACCAGCAGAGATACACG 
gyrB  gyrB-F TGTAAAACGACGGCCAGTGCNGGRTCYTTYTCYTGRCA 
 gyrB-R CAGGAAACAGCTATGACCAYGSNGGNGGNAARTTYRA 
 gyrB-sF TGTAAAACGACGGCCAGT 
 gyrB-sR CAGGAAACAGCTATGACC 
gdhB  gdhB-F GCTACTTTTATGCAACAGAGCC 
 gdhB-R GTTGAGTTGGCGTATGTTGTGC 
 gdhB-sF ACCACATGCTTTGTTATG 
 gdhB-sR GTTGGCGTATGTTGTGC 
recA  recA-F CCTGAATCTTCYGGTAAAAC 
 recA-R GTTTCTGGGCTGCCAAACATTAC 
cpn60  cpn60-F ACTGTACTTGCTCAAGC 
 cpn60-R TTCAGCGATGATAAGAAGTGG 
gpi gpi-F AATACCGTGGTGCTACG 
 gpi-R TTCAGGAGCAATCCCCCACT 
rpoD rpoD-F CGAATYGCATTGCAAAACG 
 rpoD-R CNGCAATYTTTTGYTGGAA 
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5. Phylogenic grouping based on partial rpoB gene sequencing.  
The 450-bp sequence (zone 2) of the rpoB gene was amplified using the primers  
Ac1005F (5’-GTGATAARATGGCBGGTCGT-3’) and Ac1598R (5’-CGBGCR 
TGCATYTTGTCRT-3’) as previously described.27 The phylogenic relationship 
based on the rpoB zone 2 sequence was estimated using the neighbor-joining 
method in molecular evolutionary genetic analysis software. 
 
6. Statistical analysis  
Statistical analysis was done by SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA). 
Differences between categorical variables were analyzed using the chi-square 
test (Fisher’s exact test). P values less than 0.05 were considered significant. 
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III. RESULTS 
 
1.  Collection and identification of Acinetobacter species  
Clinical isolates of Acinetobacter species were collected from 19 hospitals in 
six provinces in Korea in 2008 (Fig. 1). The 547 clinical isolates of 
Acinetobacter species were identified as A. baumannii (n = 388), Acinetobacter 
nosocomialis (n = 82), Acinetobacter pittii (n = 62), Acinetobacter bereziniae (n 
= 13), and Acinetobacter genomospecies 14TU (n = 2) (Table 3). 
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Fig. 1. The geographic location of 19 hospitals and numbers of clinical isolates 
(Acinetobacter spp., A. baumannii, and carbapenem-non-susceptible A. 
baumannii) collected in South Korea.  
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Table 3. Collection of Acinetobacter species clinical isolates 
Hospitals A. 
baumannii 
A. 
nosocomialis 
A. 
pitti 
A. 
bereziniae 
A.  
genomosp. 
14TU 
Total 
KNSM 20 5 9 0 0 34 
KNSS 30 8 4 0 0 42 
KDSS 3 0 0 0 0 3 
GYMC 19 4 2 1 0 26 
KSMC 31 5 1 0 0 37 
GMC 7 1 3 0 0 11 
MJMC 30 0 1 0 0 31 
BUSAN 23 6 1 0 1 31 
BCS 14 1 3 0 0 18 
CHA 21 3 4 7 0 35 
YMC 33 9 1 0 1 44 
YMM 28 7 11 0 0 46 
WJ 22 2 10 1 0 35 
IJMC 39 7 4 1 0 51 
CNMC 23 13 1 0 0 37 
JJ 3 0 0 0 0 3 
CSMC 11 3 2 0 0 16 
CYY 9 8 1 3 0 21 
CYH 22 0 4 0 0 26 
Total 388 82 62 13 2 547 
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2.  Carbapenem and colistin resistance patterns of Acinetobacter species 
Reduced susceptibility rates to imipenem or meropenem were 70% (272/388) 
for A. baumannii, 5% (4/82) for A. nosocomialis, 13% (8/62) for A. pitti, and 
0% (0/13) for A. bereziniae. Over 60% of resistance rates to carbapenem in A. 
baumannii were showed in 15 of 19 hospitals (Table 4). All but four 
Acinetobacter species isolates exhibited susceptibility to colistin. Only one of 
403 A. baumannii isolates (MIC, 8 g/mL) and one of 13 A. bereziniae isolates 
(MIC, 8 g/mL) showed low-level resistance to colistin. None of the 82 A. 
nosocomialis isolates and the 62 A. pitti isolates showed resistance to colistin 
(Table 5). However, both Acinetobacter genomospecies 14TU isolates showed 
high-level resistance to colistin (MIC, 32 g/mL). Interestingly, the 
Acinetobacter genomospecies 14TU ATCC17905 reference strain also showed 
high-level resistance to the drug (MIC, 64 g/mL). 
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Table 4. Carbapenem resistance rates of clinical isolates of Acinetobacter 
species collected from 19 hospitals 
Hospitals 
A. baumannii A. nosocomialis A. pitti 
no. of isolates NS (%) no. of isolates NS (%) no. of isolates NS (%) 
KNSM 20 13 (65) 5 0 9 1 
KNSS 30 23 (77) 8 1 4 1 
KDSS 3 3 (100) 0 0 0 0 
GYMC 19 9 (47) 4 0 2 0 
KSMC 31 27 (87) 5 0 1 0 
GMC 7 3 (43) 1 0 3 0 
MJMC 30 25 (83) 0 0 1 1 
BUSAN 23 22 (96) 6 0 1 1 
BCS 14 8 (57) 1 0 3 0 
CHA 21 2 (10) 3 0 4 1 
YMC 33 24 (73) 9 1 1 1 
YMM 28 23 (82) 7 0 11 1 
WJ 22 15 (68) 2 1 10 0 
IJMC 39 27 (69) 7 0 4 0 
CNMC 23 17 (74) 13 0 1 0 
JJ 3 2 (67) 0 0 0 0 
CSMC 11 8 (73) 3 1 2 0 
CYY 9 6 (67) 8 0 1 0 
CYH 22 15 (68) 0 0 4 0 
Total 388 272 (70) 82 4 (5) 62 8 (13) 
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Table 5. Antimicrobial susceptibilities to carbapenem and colistin in Acinetobacter species 
 
Abbreviations: IPM, imipenem; MEM, meropenem; CST, colistin; R, resistant; I, intermediate; S, susceptible 
Species  
(no. of isolates) 
IPM (breakpoints, mm) MEM (breakpoints, mm) CST (MIC, g/mL) 
R (≤ 13) I (14-15) S (≥16) R (≤ 13) I (14-15) S (≥16) R (≥4) S (≤ 2) 
A. baumannii (388) 221 23 144 270 2 116 1 387 
A. nosocomialis (82) 2 2 78 4 0 78 0 82 
A. pitti (62) 8 0 54 8 0 54 0 62 
A. bereziniae (13) 0 0 13 0 0 13 1 12 
A. genomospecies 14TU (2) 0 0 2 0 0 2 2 0 
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3.  Carbapenem resistance mechanisms of Acinetobacter species  
While 70% (272/388) of A. baumannii isolates exhibited intermediate or 
resistance to imipenem and/or meropenem, the majority of non-baumannii 
Acinetobacter isolates was susceptible to these drugs (Table 5). Most CNSAB 
(266/272) showed positive results on the modified Hodge test; however, none 
had positive results on the IEDDS test. The blaOXA-23 gene was detected in 
169/272 CNSAB isolates, while the ISAba1 element associated with the 
blaOXA-51-like gene was detected in 89/272 isolates. Fourteen isolates, all of 
which were collected from the same hospital, carried both genes (Table 6). 
Genes encoding OXA-24-like and OXA-58-like carbapenemases or MBLs were 
not detected in the A. baumannii isolates. Most (10/12) of the 
carbapenem-non-susceptible non-baumannii Acinetobacter (NBA) isolates 
showed positive results on the IEDDS test, suggesting the production of MBLs. 
The blaIMP-1 and the blaVIM-2 genes were detected in six and four of these NBA 
isolates, respectively. With the exception of an A. pitti isolate carrying the 
blaOXA-23 gene, no genes encoding OXA carbapenemases were detected in any of 
the NBA isolates. 
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Table 6. Carbapenem resistance mechanisms of Acinetobacter species
Species  
(no. of isolates) 
Carbapenem resistance determinants 
blaOXA-23 
only 
ISAba1-blaOXA-51 
only 
blaOXA-23, 
ISAba1-blaOXA-51 
blaOXA-24 
-like 
blaOXA-58
-like 
blaIMP-1 blaVIM-2 blaSIM-1 
A. baumannii (272) 169 89 14 0 0 0 0 0 
A. nosocomialis (4) 0 0 0 0 0 1 2 0 
A. pitti (8) 1 0 0 0 0 5 2 0 
 25 
 
4. Location of the blaOXA-23 gene 
A probe specific for the blaOXA-23 gene hybridized with 100-kb to 150-kb I-CeuI 
chromosomal fragments from A. baumannii and A. pitti isolates, respectively, 
but not with S1 nuclease-treated linearized plasmids. The 16S rDNA probe also 
hybridized with the same chromosomal fragments, suggesting the presence of 
the blaOXA-23 gene on the chromosome rather than on a plasmid. 
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Fig. 2. PFGE pattern of genomic DNA of Acinetobacter species digested by I-CeuI enzyme (a), Southern blot hybridization 
with blaOXA-23 probe (b) and 16S rRNA gene probe (c). Lane M, lambda ladder (Bio-Rad) as a DNA size marker; lanes 1 to 12, 
A. baumannii isolates; lane 13, A. pitti isolate.
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5. Grouping of A. baumannii isolates based on partial rpoB gene sequencing 
A phylogenic tree clustered the 388 A. baumannii isolates into five groups 
according to the rpoB zone 2 sequence using the neighbor-joining method (Fig. 
3). The group A isolate was defined as that carrying the same nucleotide 
sequence in zone 2 of the rpoB gene that is carried by the A. baumannii 
ATCC19606 reference strain (Table 7). The group B isolate was defined as that 
with a G-to-T substitution at the 428th nucleotide in zone 2 compared to the A. 
baumannii ATCC19606 reference strain sequence. Isolates belonging to 
subgroup B-0 had only one G428T substitution. Group C, D and E isolates were 
defined as those with a C449T, A407G and G116A substitution, respectively, in 
zone 2 compared to the A. baumannii ATCC19606 reference strain sequence 
(Table 7). Interestingly, all 272 CNSAB isolates belonged to subgroup B-0. 
However, some (37/309) isolates belonging to subgroup B-0 were susceptible to 
carbapenems. All of isolates belonging to group C, D and E were susceptible to 
carbapenems. 
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Fig. 3. Phylogenic tree of 388 isolates of A. baumannii inferred from zone 2 
sequencing of the rpoB gene. This tree was grouped using the neighbor-joining 
method in molecular evolutionary genetic analysis software. Values on the 
branches of the clusters represented the results of bootstrapping analysis. 
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Table 7. Antimicrobial susceptibilities and A. baumannii groups according to substitution in zone 2 of the rpoB gene sequence 
Species (no. of isolates)  IPM (Breakpoints, mm)* MEM (Breakpoints, mm) CST (MIC, g/mL) 
A. baumannii (388)  Group Substitution† R (≤ 13) I (14-15) S (≥16) R (≤ 13) I (14-15) S (≥16) R (≥4) S (≤ 2) 
 B (320)           
  B-0‡ G428T 221 23 65 270 2 37 0 309 
  B-1 G428T, C292T 0 0 4 0 0 4 0 4 
  B-2 G428T, C292T, G89C 0 0 5 0 0 5 0 5 
  B-3 G428T, T431A 0 0 2 0 0 2 0 2 
 C (36)           
  C-0 C449T 0 0 8 0 0 8 0 8 
  C-1 C449T, C269A 0 0 23 0 0 23 0 23 
  C-2 C449T, C239T 0 0 3 0 0 3 0 3 
  C-3 C449T, C114T 0 0 2 0 0 2 0 2 
 E (13)          
  E-0 G116A 0 0 12 0 0 12 0 12 
  E-1 G116A, C449T 0 0 1 0 0 1 0 1 
 D (5) A407G 0 0 5 0 0 5 0 5 
 A (14)  0 0 14 0 0 14 1 13 
A. nosocomialis (82)  2 2 78 4 0 78 0 82 
A. pitti (62)  8 0 54 8 0 54 0 62 
A. bereziniae (13)  0 0 13 0 0 13 1 12 
Acinetobacter genomospecies 14TU (2) 0 0 2 0 0 2 2 0 
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Abbreviations: IPM, imipenem; MEM, meropenem; CST, colistin; R, resistant; I, intermediate; S, susceptible 
* The CLSI breakpoints were applied for the interpretation of the results. 
 
†The reference sequence of A. baumannii ATCC19606 was defined as group A.  
‡There was a significant difference (P <0.001) in carbapenem susceptibility between B-0 group (88.0%) and non-B-0 groups 
(0%) by the Chi-square test (Fisher’s exact test) using SAS 9.1.3 (SAS Institute Inc., Cary, NC, USA).
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6. Clonal relationship 
Results of rep-PCR experiments on the 388 A. baumannii isolates are shown in 
Figure 4, illustrating that the A. baumannii isolates were clustered into 57 
distinct band patterns, using a clonal relationship index of >95% as a threshold. 
All 272 CNSAB isolates belonged to one of three band patterns (17, 18, or 19). 
These band patterns were similar to those of the EU-II control strain described 
by Higgins et al.
20
 A total of 57 different STs were identified in 388 A. 
baumannii isolates using MLST experiments by the method of Bartual et al.
34
, 
and the 272 CNSAB isolates were classified into five STs (ST92, ST75, ST138, 
ST137, and ST69; Fig. 4). However, the isolates of aforementioned five STs 
were identified as an identical ST, ST2 (2-2-2-2-2-2-2), by the MLST method 
described by Diancourt et al.
36
 Many (159/272) CNSAB isolates were identified 
as ST92 including 76 isolates carrying the blaOXA-23 gene, 69 isolates carrying 
the ISAba1 element associated with the blaOXA-51-like gene, and 14 isolates 
carrying both. One hundred five isolates carrying the blaOXA-23 gene (n = 93) or 
the ISAba1 element associated with the blaOXA-51-like gene (n = 12) were 
identified as ST75 (n = 64), ST137 (n = 3), or ST138 (n = 38), single-locus 
variants of ST92. The remaining eight isolates carrying the ISAba1 element 
associated with the blaOXA-51-like gene were identified as ST69, a double-locus 
variant of ST92.  
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Isolates
IJ01
SC19
CHA42
IJ40
CYH28
KSM07
GY26
YN04
CS18
IJ35
CN10
CN15
YMM14
CHA27
CHA26
CHA33
KSM20
GY12
YMC31
WJ05
CHA39
CYY17
CYY24
WJ44
YMC11
IJ22
KSM29
GY13
GY20
GM32
CHA15
YN45
YMM4
YMC26
MJ15
KS49
CHA45
KSM22
KY14
KS30
SC03
KSS21
CYM22
KMC07
CHA51
CS30
CHA18
KY23
CHA27
CYM23
KS47
YMC42
KSS36
CNM10
CYH13
CHA50
WJ02
KSS15
YMM05
MJ12
CCH15
CHA31
MJ26
KSM11
CS41
CHA39
CYH26
IJ02
Rep-PCR gltA gyrB gdhB recA cpn60 gpi rpoD ST rpoB  type no. of 
isolates Susceptible
bla OXA-23 ISAba1- bla OXA-23 +
bla OXA-51-like ISAba1 -bla OXA-51-like
1 1 3 65 45 4 4 26 148
* B-1 1 1 0 0 0
1 1 48 65 45 4 90 26 171
* B-0 1 1 0 0 0
1 1 48 65 45 4 90 26 171
* E-0 1 1 0 0 0
2 21 12 2 28 1 86 4 161
* C-1 1 1 0 0 0
3 21 48 58 42 36 83 4 176
* B-1 1 1 0 0 0
4 35 60 77 11 26 11 48 182
* B-1 1 1 0 0 0
5 36 31 70 28 4 54 4 184
* B-0 1 1 0 0 0
6 2 38 42 1 1 4 49 150
* B-1 1 1 0 0 0
7 2 38 42 1 1 4 49 150
* E-0 1 1 0 0 0
8 1 15 13 12 4 14 2 146
* C-0 1 1 0 0 0
9 1 15 13 12 4 14 2 146
* C-0 2 2 0 0 0
10 1 15 13 12 4 14 2 146
* C-0 2 2 0 0 0
11 1 15 13 12 4 12 2 20 C-0 1 1 0 0 0
12 1 31 79 43 4 25 50 157
* C-3 1 1 0 0 0
13 1 31 79 43 4 25 50 157
* C-3 1 1 0 0 0
14a 21 35 2 28 1 85 4 158
* C-1 1 1 0 0 0
14a 21 35 2 28 1 52 4 145
* C-1 1 1 0 0 0
15 1 15 12 6 28 59 32 140
* A 2 2 0 0 0
16 21 35 2 28 1 52 4 145
* C-1 1 1 0 0 0
17a 1 3 3 2 2 7 3 92 B-0 183 24 (6) 76 (20) 69 (18) 14 (4)
17a 1 47 67 28 1 10 6 143
* B-3 1 1 0 0 0
17a 1 3 3 2 2 12 3 137 B-0 3 0 0 3 0
17a 1 46 3 2 2 58 3 69 B-0 8 0 0 8 (2) 0
17b 1 3 3 2 2 50 3 138 B-0 3 1 1 1 0
17b 1 3 3 2 2 11 3 75 B-0, E-1 60 1○ 55 (14) 4 (1) 0
17b 1 47 3 2 2 7 30 141
* A 1 1 0 0 0
17b 1 15 81 1 1 72 45 152
* C-1 1 1 0 0 0
18 1 3 3 2 2 11 3 75 B-0 5 0 2 3 0
18 1 12 12 11 4 10 3 17 B-2 5 5 0 0 0
18 1 3 3 2 2 50 3 138 B-0, E-0 37 1○ 35 (9) 1 0
19a 1 15 2 28 1 25 32 156
* C-1 6 6 0 0 0
19b 1 56 2 44 1 52 6 160
* C-1 1 1 0 0 0
19c 1 47 67 28 1 82 6 149
* B-3 1 1 0 0 0
19d 1 15 2 28 1 52 32 110 C-1 4 4 0 0 0
19e 1 15 2 28 1 52 32 110 C-1 2 2 0 0 0
20 33 21 12 49 1 54 7 177
* C-0 1 1 0 0 0
21 1 15 2 28 1 52 32 110 C-1 1 1 0 0 0
22a 21 12 2 28 32 83 4 151
* C-1 2 2 0 0 0
22a 21 35 2 28 1 84 4 153
* C-1 1 1 0 0 0
22b 21 55 13 28 1 84 2 154
* C-0 1 1 0 0 0
23 37 53 13 47 32 64 52 185
* B-0 1 1 0 0 0
24 1 15 12 6 28 59 3 139
* A 1 1 0 0 0
25 1 57 78 12 1 10 51 159
* C-2 1 1 0 0 0
26 1 57 78 12 1 25 51 155
* C-2 1 1 0 0 0
27 1 57 78 12 1 10 51 159
* C-2 1 1 0 0 0
28 33 12 40 26 32 83 5 167
* D 1 1 0 0 0
29 33 12 40 26 32 84 5 164
* D 1 1 0 0 0
30 33 12 40 26 32 91 5 163
* D 1 1 0 0 0
31 33 12 40 26 25 84 5 165
* D 1 1 0 0 0
32 33 12 40 26 32 87 5 166
* D 1 1 0 0 0
33 35 62 75 28 35 7 30 179
* A 2 2 0 0 0
34 1 17 82 39 1 92 7 175
* A 3 3 0 0 0
35a 1 17 81 1 1 91 26 183
* B-0 1 1 0 0 0
35b 1 54 62 31 4 55 45 147
* E-0 3 3 0 0 0
35c 1 3 15 2 2 7 3 106 B-0 1 1 0 0 0
36 1 58 29 2 4 9 53 173
* B-0 1 1 0 0 0
37a 38 59 80 48 18 58 43 186
* B-0 1 1 0 0 0
37b 40 1 83 6 4 7 3 162
* B-0 3 3 0 0 0
38 31 61 70 46 16 58 6 178
* E-0 1 1 0 0 0
39 1 63 12 6 28 59 30 180
* A 1 1 0 0 0
40 1 34 80 28 1 72 45 172
* B-0 1 1 0 0 0
41 1 12 80 28 35 89 30 170
* E-0, E-1 3 3 0 0 0
42 1 34 70 28 4 90 45 169
* E-0 1 1 0 0 0
43 1 12 65 45 4 88 26 168
* E-0 1 1 0 0 0
44 11 27 14 21 15 22 15 174
* B-0 1 1 0 0 0
45 21 35 2 28 22 52 4 144
* C-1 1 1 0 0 0
46 1 64 76 1 23 81 32 181
* A 1 1 0 0 0
47 10 12 4 11 1 9 30 142
* A 3 3 0 0 0
Total 388 116 (30) 169 (44) 89 (23) 14 (4)
no. (%) of isolates with carbapenem susceptibility
Carbapenem-resistance determinant 
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Fig. 4. Rep-PCR banding patterns and STs of 388 isolates of A. 
baumannii. Isolates that showed >95% similarity were assigned the same 
banding pattern number, and a small letter (a to e) was given to isolates 
with >90% similarity. The asterisks indicate novel STs found in this study. 
Open circles indicate the number of isolates belonged to E group. 
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IV. DISCUSSION 
A. baumannii is an opportunistic pathogen and the most common cause of 
serious nosocomial infections, especially in intensive care units
3, 5
. The aims 
of present study were to investigate: resistance patterns and mechanisms to 
carbapenems and colistin in Acinetobacter species isolates from clinical 
specimens of patients hospitalized at 19 different hospitals in Korea, the 
epidemiological traits of CNSAB isolates, and the usefulness of phylogenic 
grouping based on partial rpoB gene sequencing in defining the 
epidemiological traits of CNSAB.  
The increasing prevalence of carbapenem-resistant A. baumannii clinical 
isolates has become a serious worldwide problem. The prevalence of 
antibiotic-resistant bacteria varies greatly from country to country. 
Carbapenem resistance rates of A. baumannii isolates were high over 50% in 
Greece, Spain, Portugal and Turkey.
37
 The Korean Nationwide Surveillance of 
Antimicrobial Resistance (KONSAR) study group reported that 
imipenem-resistance rate of Acinetobacter species steadily increased from 1% 
in 1997 to 22% in 2007, and after that the increase was drastic, reaching 51% 
in 2009.
38, 39
 In the present study, imipenem or meropenem non-susceptible A. 
baumannii isolates was approximately 70 % (range 10-87%). High resistance 
rates to imipenem or meropenem in A. baumannii were revealed in almost 
hospitals. The increasing carbapenem resistance in A. baumannii is very 
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worrisome considering the fact those isolates show multi-drug resistance to 
the other class antibiotics such as aminoglycosides and fluoroquinolones
40
. 
Colistin and polymixin B are the only potent therapeutic options available for 
treatment of severe hospital acquired infections caused by multi-drug resistant 
A. baumannii. Results of our study correspond well with those of Ko et al.’ 
study which reported subgroups of A. baumannii using partial rpoB gene 
sequences. However, colistin resistance rates differ from the result of this 
study. Although Ko et al.
19
 reported high rates of resistance to colistin and 
polymixin B in A. baumannii, colistin-resistant A. baumannii isolate was rare 
until now as shown in this study. Their study is different from this study in 
that small number of hospitals and antimicrobial susceptibility testing method. 
Molecular characterization of the 272 CNSAB isolates using multilocus 
sequencing typing identified five sequence types: ST92, ST75, ST137, ST138, 
and ST69. The CNSAB of ST92, one of its single-locus variants (ST75, 
ST138, and ST137), or its double-locus variant (ST69). ST92 and its 
single-locus variants can be clustered into a single clonal complex 92 because 
they share five to six of seven housekeeping gene loci. The results of Institute 
Pasteur MLST scheme also supported the clonally relatedness of the isolates 
in a broader sense, which they share an identical ST, ST 2. CC92 also includes 
other single-locus variants of ST92, including ST118 (1-3-3-2-2-3-3) 
identified from an isolate from France, ST88 (1-3-3-2-2-10-3) and ST90 
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(1-3-3-2-2-62-3) from China, and ST4 (1-12-3-2-2-7-3) from the UK. 
Therefore, clonal expansion of A. baumannii CC92 may be the main cause of 
the recent worldwide dissemination of CNSAB.  
A. baumannii isolates clustered into five groups according to the sequence of 
zone 2 of the rpoB gene. Grouping correlated well with the carbapenem 
resistance profiles of the A. baumannii isolates. All 272 CNSAB isolates 
belonged to subgroup B-0, while all of the isolates belonging to the other 
groups were susceptible to carbapenems. Subgroup B-0 was comprised of 37 
carbapenem-susceptible isolates and 272 CNSAB isolates, including 169 
isolates carrying the blaOXA-23 gene, 89 isolates carrying the ISAba1 element 
upstream of the blaOXA-51-like gene, and 14 isolates carrying both (Fig. 4). It 
was interesting that only A. baumannii isolates with the single G428T 
substitution in zone 2 of the rpoB gene acquired carbapenem-resistance 
determinants. Further studies are needed to investigate the reasons for these 
phenomena. CNSAB isolates of CC92 with a G428T substitution in zone 2 of 
the rpoB gene were widely disseminated in Korea, as has been reported in 
European countries and China.  
While the blaOXA-23 gene has mainly been detected in A. baumannii, reports of 
NBA isolates harboring the OXA carbapenemase are rare. Recently, two A. 
pitti isolates carrying the blaOXA-23 gene were reported in the Irish Republic.
41
 
One A. pitti isolate harboring chromosome-borne OXA-23 was identified in  
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this study. To our knowledge, this is the second report of an OXA-23-produc 
-ing NBA isolate. 
In this study, only one of 403 A. baumannii isolates was identified as 
colistin-resistant, in contrast to results reported by Ko et al.
9
 Interestingly, 
both Acinetobacter genomospecies 14TU showed resistance to colistin. 
Furthermore, the Acinetobacter genomospecies 14TU ATCC 17905 reference 
strain also showed resistance to colistin. These results suggest that the 
Acinetobacter genomospecies 14TU may be intrinsically resistant to colistin, 
as described by Nemec et al.
42
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V. CONCLUSION 
A total of 547 non-duplicate clinical isolates of Acinetobacter species were 
collected from 19 hospitals. Reduced susceptibility rates to imipenem or 
meropenem were 70% (272/388) for A. baumannii, 5% (4/82) for A. 
nosocomialis, 13% (8/62) for A. pitti, and 0% (0/13) for A. bereziniae. Over 
60% of resistance rates to carbapenems in A. baumannii were showed in 15 of 
19 hospitals. Colistin-resistant A. baumannii isolates was rare, 0.25% (1/388). 
However, all of isolates of Acinetobacter genomospecies 14 TU as well as 
Acinetobacter genomospecies 14TU ATCC 17905 were resistant to colistin, 
resulting in possibility of natural resistance to colistin in Acinetobacter 
genomospecies 14TU. 
The 272 CNSAB isolates were clustered into CC92, sharing alleles at five or 
six of seven housekeeping gene loci. ST92 was the predominant ST and was 
associated with European clone II. CNSAB of CC92 carried the blaOXA-23 gene, 
the blaOXA-51-like gene preceded by ISAba1 or both. Sequence-based analysis 
of the rpoB gene showed single-nucleotide substitutions in zone 2 of the rpoB 
gene, resulting in division into five groups (A to E groups). All CNSAB 
isolates belonged to subgroup B-0 with a G428T substitution in zone 2. 
CNSAB isolates of CC92 with the G428T substitution in zone 2 of the rpoB 
gene are disseminated nationwide in Korea. A. baumannii with the G428T 
substitution in zone 2 may be more likely to acquire carbapenem resistance 
than are other isolates. 
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ABSTRACT (IN KOREAN) 
 
 
국내 분리 Acinetobacter 균종의 carbapenem과  
colistin 내성 양상, 기전 및 분자역학적 특성  
 
<지도교수 정석훈> 
 
연세대학교 대학원 의학과 
 
이 양 순 
 
 
최근 carbapenem 내성인 Acinetobacter 균종의 증가는 이 세균에 
의한 감염증 환자의 치료에 있어서 항균제 선택을 크게 제한함으로 
많은 우려가 되고 있다. Colistin이 다약제 내성 A. baumannii에 의한 
병원내 감염 환자의 유일한 치료제이나, 이에 대한 내성 균주도 
출현하였다. 본 연구에서는 우리나라 전국 병원에서 수집된 
Acinetobacter 균종별 carbapenem과 colistin의 내성양상 및 기전을 
분석하였다. 또한 A. baumannii 균주를 대상으로 multilocus sequencing 
typing (MLST) 방법과 rpoB 유전자 염기서열 분석을 통하여, 
carbapenem 내성인 A. baumannii의 분자역학적인 특성을 규명하고자 
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하였다.  
2008년 전국 6개 지역 19개 주요 병원에서 분리된 Acinetobacter 
균종 547주를 수집하였다. Imipenem 혹은 meropenem에 감수성이 
저하된 균주는 각각 A. baumannii 65% (272/388), A. nosocomialis 5% 
(4/82),  A. pitti 13% (8/62) 이었고, A. bereziniae 은 모두 감수성이었다. 
Colistin 내성인 균주는 A. baumannii와 A. bereziniae 각각 1주 였고 
Acinetobacter genomospecies 14 TU 2주가 colistin 에 모두 내성이었다. 
분리된 A. baumannii 388주에 대해서 MLST 및 rpoB 유전자의 
다중중합효소반응 및 염기서열 분석을 시행하였다. MLST 분석 결과, 
carbapenem에 감수성이 저하된 A. baumannii은 모두 5개의 sequence 
type (ST), ST92, ST75, ST137, ST138, ST69에 속하였고, 이들은 7개의 
유전자중 5-6개 유전자가 동일한 clonal complex 92 를 이루고 있었다. 
이 중에서 ST92는 세계적으로 분포하고 있는 European clone II 에 
속하는 ST으로 본 연구에서 가장 많이 분리되었다. CC92에 속하는 
carbapenem 비감수성 A. baumannii의 carbapenem 내성기전은 
OXA-23형 유전자를 가진 경우가 169주, OXA-51형를 과발현한 
균주는 89주, OXA-23형과 OXA-51형을 과발현한 균주는 14주였다. 
한편, rpoB 유전자의 zone2 부분을 PCR 및 염기서열 분석하였을 때, 
특정 위치의 치환기에 따라 5개군(A-E군)으로 분류됨을 알 수 
있었다. 특히, carbapenem에 비감수성인 A. baumannii 272주는 모두 
rpoB 유전자 zone 2의 428번째 염기가 G에서 T로 치환된 B-0군에 
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속하였다. B-0군 이외의 군에서는 carbapenem 내성인 균주가 없었다.  
결론적으로, 우리나라 환자에서 분리된 Acinetobacter 균종 중 
carbapenem 내성률은 A. baumannii가 가장 높아 70%에 이르렀다. 
반면, colistin 내성률은 현재까지는 매우 낮음을 알 수 있었다. 
분자역학적인 연구결과, rpoB 유전자 zone2의 G428T 치환을 가진 
carbapenem 내성 A. baumannii clonal complex 92 균주들이 우리나라에 
널리 확산되어 있음을 확인할 수 있었다. 또한, rpoB 유전자 zone2의 
G428T 치환기를 가진 A. baumannii는 다른 균주들보다 carbapenem 
내성을 잘 획득하여 확산된 것으로 판단되었다. 
 
 
 
 
 
 
 
 
 
 
---------------------------------------------------------------------------------------------- 
핵심되는 말 : Acinetobacter baumannii, clonal complex 92, European clone 
II, multilocus sequence typing, carbapenem, colistin  
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